A Phase 3 interventional study of Eltrombopag and Placebo in Idiopathic Thrombocytopenic Purpura, sponsored by GlaxoSmithKline. Completed at 51 sites in 13 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2015-03-10.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 10th largest by enrollment, is one of 4 that started in 2012, is one of 9 in phase 3, and was the 11th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 18–75
Renata PLC · Sites in Bangladesh
Ages 18–70
Nahda University · Sites in Egypt
Ages 18–65
Novartis Pharmaceuticals
Ages 5–17
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–80
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 9 · Phase 4 5
First in 2005; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 92 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 40 across the 36 interventional studies. Of the 25 that completed or were terminated, 14 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 36 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
11 studies in Purpura, Thrombocytopenic, Idiopathic by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 11 finished, 6 (55%) have results posted.
Among the 11 studies in Purpura, Thrombocytopenic, Idiopathic by GlaxoSmithKline, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2012, is one of 4 in phase 3, and was the 10th registered.
GlaxoSmithKline’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2005.
1 of the studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07189910Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 11 in Purpura, Thrombocytopenic, Idiopathic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the efficacy, safety and tolerability of eltrombopag in children with previously treated chronic immune thrombocytopenia who are between 1 and 17 years of age. This is a 2 part study. In part 1, patients will be randomized to receive either eltrombopag or placebo for 13 weeks. All patients who complete part 1 will enter part 2. In part 2, all patients will receive 24 weeks of eltrombopag.
This is a two part, double-blind, randomized, placebo-controlled and open-label Phase III study to investigate the efficacy, safety and tolerability of eltrombopag in pediatric patients with previously treated chronic ITP. In Part 1, patients will be randomized to receive eltrombopag or placebo in a 13-week double-blind, placebo-controlled treatment period. After completing Part 1, patients will begin Part 2, in which they will receive eltrombopag in an open-label manner during a 24-week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1, double-blind treatment group
Drug: Eltrombopag
Part 1, double-blind treatment group
Drug: Placebo
Part 2, open-label
Drug: Eltrombopag
Thrombopoietin receptor agonist
Placebo with no active pharmaceutical ingredient
Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1
Participants who achieved a platelet count \>=50 Gi/L for at least 6 out of 8 weeks, between Weeks 5 and 12 of Part 1, were reported.
Time frame: From Week 5 up to Week 12 of Part 1
Percentage of Responders
Percentage of participants who responded (defined as platelet count \>= 50 Gi/L in absence of rescue) at least once up to week 12 of Part 1 (Odds of achieving a platelet count \>=50 Gi/L during the first 12 weeks of Part 1)
Time frame: From Week 1 up to Week 12 of Part 1
Number of Participants Achieving a Platelet Count >=50 Gi/L at Any Time During the First 12 Weeks of Part 1
Participants who achieved a platelet count \>=50 Gi/L at any time during the first 12 weeks of Part 1 were reported.
Time frame: From Baseline up to Week 12 of Part 1
Number of Participants Achieving a Platelet Count >=50 Gi/L at Any Time During the First 6 Weeks of Part 1
Participants who achieved a platelet count \>=50 Gi/L at any time during the first 6 weeks of Part 1 were reported.
Time frame: From Baseline up to Week 6 of Part 1
Weighted Mean Platelet Count
The weighted mean platelet count is defined as "the area under the platelet-time curve divided by the duration of the study (12 weeks)". Weighted mean platelet counts from baseline to week 12 of the randomized period was compared between placebo and eltrombopag using an analysis of covariance model (ANCOVA) adjusting for baseline platelet count and age cohort. For each subject the area between two adjacent visits with platelet counts was calculated. The area was calculated for all pairs of adjacent visits starting at Day 1 of randomized period and then the total sum of all the areas was divided by the total duration of time during the randomized period. For each subject, this method calculates an 'average' platelet count and it allows the possibility that subjects may have had different number of assessments during different times relative to baseline.
Time frame: Baseline and Week 12 of Part 1
Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the First 12 Weeks of Part 1
The maximum duration for which a participant continuously maintained a platelet count \>=50 Gi/L was calculated and summarized for the first 12 weeks of Part 1. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If a participant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day.
Time frame: From Baseline up to Week 12 of Part 1
Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 1
Rescue treatment is defined as either a new immune (idiopathic) thrombocytopenic purpura (ITP) medication, an increase in the dose of a concomitant ITP medication from Baseline, a platelet transfusion, or a splenectomy.
Time frame: From Baseline up to Week 12 of Part 1
Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 1
The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0=no bleeding; Grade 1=petechiae; Grade 2=mild blood loss; Grade 3=gross bleeding; Grade 4=debilitating blood loss. The WHO grades were dichotomized into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. Baseline was defined as the Day 1 assessment or the latest possible screening assessment.
Time frame: From Baseline through Follow-up of Part 1
Number of Participants Who Achieved a Platelet Count >=50 Gi/L at Any Time During Part 2
Participants who achieved a platelet count \>=50 Gi/L at any time during Part 2 (up to Week 24) were reported.
Time frame: From Baseline up to Week 24 of Part 2
Number of Weeks in Which Participants Achieved a Platelet Count >=50 Gi/L, Between Weeks 4 and 24 of Part 2
Platelet response was analyzed after Week 4 for the eltrombopag-only period to allow participants who had been randomized to placebo in the Randomized Period time to escalate to their optimal dose of eltrombopag. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If the participant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day.
Time frame: From Week 4 up to Week 24 of Part 2
Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During Part 2
The maximum duration for which a participant continuously maintained a platelet count of \>=50 Gi/L was calculated and summarized for the 24 weeks of eltrombopag dosing (Part 2). Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If the participant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day.
Time frame: From Baseline up to Week 24 of Part 2
Number of Participants Who Reduced or Discontinued Baseline Concomitant ITP Medications During Part 2 Without Requiring Subsequent Rescue Therapy
Participants who discontinued or had a sustained reduction of a baseline immune (idiopathic) thrombocytopenic purpura (ITP) medication during the 24 weeks of Part 2 (Open-Label Period) and without requiring subsequent rescue therapy. For participants randomized to placebo in Part 1, Baseline is defined as Week 13 of Part 1. For participants randomized to eltrombopag in Part 1, Baseline is defined as Day 1 of Part 1. A sustained reduction was defined as a reduction for 4 weeks or more.
Time frame: From Baseline up to Week 24 of Part 2
Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 2
Rescue treatment was defined as either a new immune (idiopathic) thrombocytopenic purpura (ITP) medication, an increase in the dose of a concomitant ITP medication from Baseline, a platelet transfusion, or a splenectomy.
Time frame: From Baseline up to Week 24 of Part 2
Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the WHO Bleeding Scale During Part 2
The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0 = no bleeding, Grade 1 = petechiae, Grade 2 = mild blood loss, Grade 3 = gross bleeding and Grade 4 = debilitating blood loss. The WHO Grades were dichotomized into the following categories: no bleeding = Grade 0; any bleeding = Grade 1 to 4; no clinically significant bleeding = Grade 0 to 1; clinically significant bleeding = Grade 2 to 4.
Time frame: From Baseline of Part 2 through Follow-up
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 1
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.
Time frame: From Day 1 of Treatment up to Week 13 of Part 1+ 1 day
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 2
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening; requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.
Time frame: From Day 1 of Part 2 up to Week 24 of Part 2 + 1 day
Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters at Any Time Post-Baseline During Part 1
Clinical chemistry parameters were summarized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0: Grade 0 (G0), none; Grade 1 (G1), mild; Grade 2 (G2), moderate; Grade 3 (G3), severe; Grade 4 (G4), life-threatening or disabling. Clinical chemistry parameters included: aspartate amino transferase (AST), alkaline phosphatase (ALP), total bilirubin, albumin, alanine amino transferase (ALT), prothrombin international normalized ratio (PT INR), activated partial thromboplastin time (APTT), and creatinine. The Baseline value is defined as the value taken at Day 1 or, if missing, the latest non-missing Screening value. For serum creatinine, due to the variations in creatinine, the average of the Screening and the Day 1 values will be used as Baseline. The maximum post-Baseline toxicity grade includes any scheduled or unscheduled post-Baseline assessment during Part 1.
Time frame: From Baseline up to Week 13 of Part 1
Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters at Any Time Post-Baseline During Part 2
Clinical chemistry parameters were summarized according to the NCI CTCAE, version 4.0: G0, none; G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Clinical chemistry parameters included: AST, ALP, total bilirubin, albumin, ALT, and creatinine. For participants randomized to Placebo in Part 1, the BL value for Part 2 is defined as the value taken at Week 13 of Part 1. For serum creatinine, the value taken at Week 13 of Part 1 will be used as BL. For participants randomized to Eltrombopag in Part 1, the BL value is defined as the value taken on Day 1 or, if missing, the latest non-missing Screening value. For serum creatinine, due to the variations in creatinine, the average of the Screening and the Day 1 values will be used as BL. For participants who do not have both a Screening and Day 1 value, the Screening or Day 1 value will be used as BL. The maximum post-BL toxicity grade includes any scheduled or unscheduled post-BL assessment.
Time frame: From Baseline (BL) of Part 2 through Follow-up
Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Hematology Parameters at Any Time Post-Baseline During Part 1
Hematology parameters were summarized according to the NCI CTCAE, version 4.0: G0, none; G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Hematology parameters included: leukocytes, neutrophils, hemoglobin (increased), hemoglobin (anemia), lymphocytes (increased), and lymphocytes (decreased). The Baseline value is defined as the value taken at Day 1 or, if missing, the latest non-missing Screening value. The maximum post-Baseline toxicity grade includes any scheduled or unscheduled post-Baseline assessment during Part 1.
Time frame: From Baseline up to Week 13 of Part 1
Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Hematology Parameters at Any Time Post-Baseline During Part 2
Hematology parameters were summarized according to the NCI CTCAE, version 4.0: G0, none, G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Hematology parameters included: leukocytes, neutrophils, hemoglobin (increased), hemoglobin (anemia), lymphocytes (increased), and lymphocytes (decreased). For participants randomized to Placebo in Part 1, the BL value for Part 2 is defined as the value taken at Week 13 of Part 1. For participants randomized to Eltrombopag in Part 1, the BL value is defined as the value taken on Day 1 or, if missing, the latest non-missing Screening value. For participants who do not have both a Screening and Day 1 value, the Screening or Day 1 value will be used as BL. The maximum post-BL toxicity grade includes any scheduled or unscheduled post-BL assessment.
Time frame: From Baseline up to Week 24 of Part 2 and Follow-up Weeks 1 to 4 (up to Study Week 41)
Number of Participants With Vital Sign Data Falling Outside the Reference Ranges (RR) at the Indicated Visit During Part 1
Vital sign measurements were taken before any blood draws and included systolic blood pressure(SBP), diastolic blood pressure(DBP), and heart rate(HR). The number of participants are reported with vital sign data falling outside the standard reference ranges RR as reference range high(RRH) and reference range low(RRL). The Baseline(BL) value is defined as the value taken at Day 1 or if missing, the latest non-missing SCR value. RR for Blood Pressure (mmHg) are read as: Lower Limit of Normal, Normal Range, Upper Limit of Normal. For Ages 1 to 5 years (yrs) ranges are SBP \<85, 85 to 115, \>115; DBP \<45, 45 to70, \>70. Ages 6 to 11 yrs: SBP \<85, 85 to 120, \>120;, DBP \<50, 50 to 75, \>75. Ages 12 to 17 yrs: SBP \<95, 95 to 135, \>135; DBP \<55, 55 to 85, \>85. RR for HR(bpm) are ages 1 to \< 3 yrs: \<90, 90 to 140, \>140; ages 3 to \< 5 yrs: \<75, 75 to 130, \>130, ages 5 to \< 8yrs: \<65, 65 to 115, \>115; ages 8 to \< 12yrs: \<55, 55 to 110, \>110; and ages 12 to 18 yrs: \<55, 55 to 110, \>110.
Time frame: From Screening (SCR) up to Week 13 of Part 1
Number of Participants With Vital Sign Data Falling Outside the Reference Ranges (RR) at the Indicated Visit During Part 2
Vital sign measurements were taken before any blood draw and included systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate(HR). The number of participants are reported with vital sign data falling outside the standard RR as reference range high(RRH) and reference range low(RRL) from SCR up to Week 24 of Part 2 and from Follow-up Week 1 to Week 4. RR for Blood Pressure(mmHg) are read as: Lower Limit of Normal, Normal Range, Upper Limit of Normal. For Ages 1 to 5 years (yrs) ranges are SBP \<85, 85 to 115, \>115; DBP \<45, 45 to70, \>70. Ages 6 to 11 yrs: SBP \<85, 85 to 120, \>120; DBP \<50, 50 to 75, \>75. Ages 12 to 17 yrs: SBP \<95, 95 to 135, \>135; DBP \<55, 55 to 85, \>85. RR for HR (bpm) are ages 1 to \< 3 yrs: \<90, 90 to 140, \>140; ages 3 to \< 5 yrs: \<75, 75 to 130, \>130, ages 5 to \< 8yrs: \<65, 65 to 115, \>115; ages 8 to \< 12yrs: \<55, 55 to 110, \>110; and ages 12 to 18 yrs: \<55, 55 to 110, \>110.
Time frame: From Week 1 up to Week 24 of Part 2 and Follow-up Week 1 to Week 4 (up to Week 41)
Number of Participants With a Change in Visual Acuity Since Baseline at Week 12 of Part 1
The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. Change in visual acuity results are presented as No (no change from Baseline), Not Clinically Significant (NCS), Improvement, and Worsening since Baseline. The Baseline value was obtained at the Screening Visit.
Time frame: Baseline and Week 12 of Part 1
Number of Participants With a Change in Visual Acuity Since Baseline at Week 24 of Part 2
The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. Change in visual acuity results are presented as No Change, NCS, Improvement, and Worsening since Baseline. The Baseline value was obtained at the Screening Visit.
Time frame: Baseline and Week 24 of Part 2
Number of Participants With a Change in Visual Acuity Since Baseline at Follow-Up Week 24
The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. Change in visual acuity results are presented as No Change, NCS, Improvement, and Worsening since Baseline. The Baseline value was obtained at the Screening Visit.
Time frame: Baseline and Follow-Up Week 24 (Study Week 61)
Number of Participants With Worsening Visual Acuity Due to Cataracts at Week 12 of Part 1
The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. The number of participants with worsening visual acuity due to cataracts at Week 12 of Part 1 are presented. Change due to cataracts is categorized as "Yes" or "No."
Time frame: Baseline and Week 12 of Part 1
Number of Participants With Worsening Visual Acuity Due to Cataracts at Week 24 of Part 2
The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. The number of participants with worsening visual acuity due to cataracts at Week 24 of Part 2 are presented. Change due to cataracts is categorized as "Yes" or "No.
Time frame: Baseline and Week 24 of Part 2
Number of Participants With Worsening Visual Acuity Due to Cataracts at Follow-Up Week 24
The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. The number of participants with worsening visual acuity due to cataracts at Follow-up Week 24 are presented. Change due to cataracts is categorized as "Yes" or "No."
Time frame: Baseline and Follow-Up Week 24 (Week 61)
Pharmacokinetic (PK) Assessments for Eltrombopag for AUC (0-t)
Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. AUC(0-t) is defined as the area under the concentration-time curve over the dosing interval. The AUC(0-t) for a 50mg dose was estimated for each cohort. From the final model, a single value of each PK parameter was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.
Time frame: Part 1 Weeks 2, 4, 6, 8, 10, 12, and Part 2 Weeks 1-12 (Study Weeks 13 - 37)
Pharmacokinetic (PK) Assessments for Eltrombopag for Cmax
Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. Cmax is defined as the maximum observed concentration. The Cmax for a 50mg dose was estimated for each cohort. From the final model, a single value of each PK parameter was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.
Time frame: Part 1 Weeks 2, 4, 6, 8, 10, 12, and Part 2 Weeks 1-12 (Study Weeks 13 - 37)
Pharmacokinetic (PK) Assessments for Eltrombopag for Apparent Oral Clearance (CL/F) and Apparent Intercompartmental Clearance (Q/F)
Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. CL/F is defined as the apparent oral clearance from plasma and Q/F is defined as apparent intercompartmental clearance. These parameters are dose independent. From the final model, a single value of each PK parameter was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort.
Time frame: Part 1 Weeks 2, 4, 6, 8, 10, 12, and Part 2 Weeks 1-12 (Study Weeks 13 - 37)
PK Assessments for Eltrombopag for Apparent Central Volume (Vc/F) and Apparent Peripheral Volume (Vp/F)
Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. Vc/F is defined as the volume of the central (e.g. plasma) compartment and Vp/F is defined as the volume of the peripheral compartment. These parameters are dose independent. From the final model, a single value of each PK parameter was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort.
Time frame: Part 1 Weeks 2, 4, 6, 8, 10, 12, and Part 2 Weeks 1-12 (Study Weeks 13 - 37)
Population PK Model Point Estimate for Eltrombopag for Absorption Rate-constant (Ka)
Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. Ka is defined as the absorption rate constant. This parameter is dose independent, and the population estimate Ka is reported.
Time frame: Part 1 Weeks 2, 4, 6, 8, 10, 12, and Part 2 Weeks 1-12 (Study Weeks 13 - 37)
Pediatric participants meeting eligibility criteria were enrolled into 3 cohorts depending upon age. Cohort 1 enrolled participants who were between 12 and 17 years old, Cohort 2 enrolled participants who were between 6 and 11 years old, and Cohort 3 enrolled participants who were between 1 and 5 years old.
| Milestone | Part 1 (Randomized Period)-Placebo | Part 1 (Randomized Period)-Eltrombopag | Part 2 (Open-Label Period) Eltrombopag |
|---|---|---|---|
| Started | 29 | 63 | 0 |
| Completed | 28 | 61 | 0 |
| Not completed | 1 | 2 | 0 |
| Withdrew: Adverse event | 1 | 2 | 0 |
| Milestone | Part 1 (Randomized Period)-Placebo | Part 1 (Randomized Period)-Eltrombopag | Part 2 (Open-Label Period) Eltrombopag |
|---|---|---|---|
| Started | 0 | 0 | 87 |
| Completed | 0 | 0 | 80 |
| Not completed | 0 | 0 | 7 |
| Withdrew: Adverse event | 0 | 0 | 4 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 |
| Withdrew: Withdrawal by parent or guardian | 0 | 0 | 1 |
Participants who achieved a platelet count \>=50 Gi/L for at least 6 out of 8 weeks, between Weeks 5 and 12 of Part 1, were reported.
| Participants | Part 1 (Randomized Period)- Placebo | Part 1 (Randomized Period)-Eltrombopag |
|---|---|---|
| Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1 | 1 | 25 |
Percentage of participants who responded (defined as platelet count \>= 50 Gi/L in absence of rescue) at least once up to week 12 of Part 1 (Odds of achieving a platelet count \>=50 Gi/L during the first 12 weeks of Part 1)
| Percentage of participants | Part 1 (Randomized Period)-Placebo | Part 1 (Randomized Period) - Eltrombopag |
|---|---|---|
| Week 1 | 0 | 15.9 |
| Week 2 | 3.4 | 23.8 |
| Week 3 | 0 | 31.7 |
| Week 4 | 6.9 | 36.5 |
| Week 5 | 6.9 | 47.6 |
| Week 6 | 6.9 | 38.1 |
| Week 7 | 10.3 | 44.4 |
| Week 8 | 3.4 | 44.4 |
| Week 9 | 3.4 | 42.9 |
| Week 10 | 3.4 | 52.4 |
| Week 11 | 6.9 | 49.2 |
| Week 12 | 3.4 | 58.7 |
Participants who achieved a platelet count \>=50 Gi/L at any time during the first 12 weeks of Part 1 were reported.
| Participants | Part 1 (Randomized Period)-Placebo | Part 1 (Randomized Period) - Eltrombopag |
|---|---|---|
| Number of Participants Achieving a Platelet Count >=50 Gi/L at Any Time During the First 12 Weeks of Part 1 | 6 | 47 |
Participants who achieved a platelet count \>=50 Gi/L at any time during the first 6 weeks of Part 1 were reported.
| Participants | Part 1 (Randomized Period)-Placebo | Part 1 (Randomized Period)-Eltrombopag |
|---|---|---|
| Number of Participants Achieving a Platelet Count >=50 Gi/L at Any Time During the First 6 Weeks of Part 1 | 5 | 39 |
The weighted mean platelet count is defined as "the area under the platelet-time curve divided by the duration of the study (12 weeks)". Weighted mean platelet counts from baseline to week 12 of the randomized period was compared between placebo and eltrombopag using an analysis of covariance model (ANCOVA) adjusting for baseline platelet count and age cohort. For each subject the area between two adjacent visits with platelet counts was calculated. The area was calculated for all pairs of adjacent visits starting at Day 1 of randomized period and then the total sum of all the areas was divided by the total duration of time during the randomized period. For each subject, this method calculates an 'average' platelet count and it allows the possibility that subjects may have had different number of assessments during different times relative to baseline.
| Gi/L | Part 1 (Randomized Period)-Placebo | Part 1 (Randomized Period) - Eltrombopag |
|---|---|---|
| Baseline | 14.2 ± 8.01 | 14.0 ± 8.09 |
| Week 12 | 23.7 ± 19.56 | 63.9 ± 46.68 |
The maximum duration for which a participant continuously maintained a platelet count \>=50 Gi/L was calculated and summarized for the first 12 weeks of Part 1. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If a participant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day.
| Weeks | Part 1 (Randomized Period)-Placebo | Part 1 (Randomized Period) - Eltrombopag |
|---|---|---|
| Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the First 12 Weeks of Part 1 | 0.4 ± 1.50 | 3.3 ± 3.13 |
Rescue treatment is defined as either a new immune (idiopathic) thrombocytopenic purpura (ITP) medication, an increase in the dose of a concomitant ITP medication from Baseline, a platelet transfusion, or a splenectomy.
| Participants | Part 1 (Randomized Period)-Placebo | Part 1 (Randomized Period) - Eltrombopag |
|---|---|---|
| Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 1 | 7 | 12 |
The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0=no bleeding; Grade 1=petechiae; Grade 2=mild blood loss; Grade 3=gross bleeding; Grade 4=debilitating blood loss. The WHO grades were dichotomized into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. Baseline was defined as the Day 1 assessment or the latest possible screening assessment.
| Participants | Part 1 (Randomized Period)-Placebo | Part 1 (Randomized Period) -Eltrombopag |
|---|---|---|
| Baseline, Any bleeding n=29,63 | 20 | 45 |
| Baseline, Significant bleeding n=29,63 | 6 | 16 |
| Week 1, Any bleeding n=29,63 | 19 | 41 |
| Week 1, Significant bleeding n=29,63 | 3 | 8 |
| Week 2, Any bleeding n=29,63 | 19 | 33 |
| Week 2, Significant bleeding n=29,63 | 6 | 6 |
| Week 3, Any bleeding n=28,62 | 18 | 32 |
| Week 3, Significant bleeding n=28,62 | 3 | 7 |
| Week 4, Any bleeding n=29, 62 | 20 | 27 |
| Week 4, Significant bleeding n=29, 62 | 4 | 4 |
| Week 5, Any bleeding n=27, 62 | 18 | 22 |
| Week 5, Significant bleeding n=27, 62 | 2 | 5 |
| Week 6, Any bleeding n=28, 62 | 17 | 24 |
| Week 6, Significant bleeding n=28, 62 | 0 | 5 |
| Week 7, Any bleeding n=28, 63 | 14 | 20 |
| Week 7, Significant bleeding n=28, 63 | 1 | 1 |
| Week 8, Any bleeding n=28, 63 | 17 | 24 |
| Week 8,Significant bleeding n=28, 63 | 1 | 4 |
| Week 9, Any bleeding n=27, 61 | 18 | 24 |
| Week 9, Significant bleeding n=27, 61 | 3 | 4 |
| Week 10, Any bleeding n=28, 62 | 17 | 20 |
| Week 10, Significant bleeding n=28, 62 | 2 | 4 |
| Week 11, Any bleeding n=28, 61 | 16 | 26 |
| Week 11, Significant bleeding n=28, 61 | 3 | 8 |
| Week 12, Any bleeding n=28, 61 | 16 | 23 |
| Week 12, Significant bleeding n=28, 61 | 2 | 3 |
| Follow-up Week 1, Any bleeding n=0,2 | 0 | 1 |
| Follow-up Week 1, Significant bleeding n=0,2 | 0 | 0 |
| Follow-up Week 2, Any bleeding n=0,2 | 0 | 1 |
| Follow-up Week 2, Significant bleeding n=0,2 | 0 | 0 |
| Follow-up Week 3, Any bleeding n=0,3 | 0 | 2 |
| Follow-up Week 3, Significant bleeding n=0,3 | 0 | 1 |
| Follow-up Week 4, Any bleeding n=0,1 | 0 | 1 |
| Follow-up Week 4, Significant bleeding n=0,1 | 0 | 1 |
| Any follow-up Week, Any bleeding n=0,3 | 0 | 2 |
| Any Follow-up Week, Significant bleeding n=0,3 | 0 | 1 |
Participants who achieved a platelet count \>=50 Gi/L at any time during Part 2 (up to Week 24) were reported.
| Participants | Part 2 (Open-Label Period) - Eltrombopag |
|---|---|
| Number of Participants Who Achieved a Platelet Count >=50 Gi/L at Any Time During Part 2 | 70 |
Platelet response was analyzed after Week 4 for the eltrombopag-only period to allow participants who had been randomized to placebo in the Randomized Period time to escalate to their optimal dose of eltrombopag. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If the participant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day.
| Weeks | Part 2 (Open-Label Period) - Eltrombopag |
|---|---|
| Number of Weeks in Which Participants Achieved a Platelet Count >=50 Gi/L, Between Weeks 4 and 24 of Part 2 | 10 ± 7.67 |
The maximum duration for which a participant continuously maintained a platelet count of \>=50 Gi/L was calculated and summarized for the 24 weeks of eltrombopag dosing (Part 2). Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If the participant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day.
| Weeks | Part 2 (Open-Label Period) - Eltrombopag |
|---|---|
| Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During Part 2 | 8.6 ± 7.84 |
Participants who discontinued or had a sustained reduction of a baseline immune (idiopathic) thrombocytopenic purpura (ITP) medication during the 24 weeks of Part 2 (Open-Label Period) and without requiring subsequent rescue therapy. For participants randomized to placebo in Part 1, Baseline is defined as Week 13 of Part 1. For participants randomized to eltrombopag in Part 1, Baseline is defined as Day 1 of Part 1. A sustained reduction was defined as a reduction for 4 weeks or more.
| Participants | Part 2 (Open-Label Period) - Eltrombopag |
|---|---|
| Number of Participants Who Reduced or Discontinued Baseline Concomitant ITP Medications During Part 2 Without Requiring Subsequent Rescue Therapy | 8 |
Rescue treatment was defined as either a new immune (idiopathic) thrombocytopenic purpura (ITP) medication, an increase in the dose of a concomitant ITP medication from Baseline, a platelet transfusion, or a splenectomy.
| Participants | Part 2 (Open-Label Period) - Eltrombopag |
|---|---|
| Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 2 | 11 |
The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0 = no bleeding, Grade 1 = petechiae, Grade 2 = mild blood loss, Grade 3 = gross bleeding and Grade 4 = debilitating blood loss. The WHO Grades were dichotomized into the following categories: no bleeding = Grade 0; any bleeding = Grade 1 to 4; no clinically significant bleeding = Grade 0 to 1; clinically significant bleeding = Grade 2 to 4.
| Participants | Part 2 (Open-Label Period) - Eltrombopag |
|---|---|
| Baseline, Any bleeding n=87 | 55 |
| Baseline, Significant bleeding n=87 | 17 |
| Week 1, Any bleeding n=86 | 29 |
| Week 1, Significant bleeding n=86 | 3 |
| Week 2, Any bleeding n=85 | 22 |
| Week 2, Significant bleeding n=85 | 2 |
| Week 3, Any bleeding n=86 | 20 |
| Week 3, Significant bleeding n=86 | 1 |
| Week 4, Any bleeding n=68 | 20 |
| Week 4, Significant bleeding n=68 | 4 |
| Week 5, Any bleeding n=61 | 21 |
| Week 5, Significant bleeding n=61 | 4 |
| Week 6, Any bleeding n=55 | 17 |
| Week 6, Significant bleeding n=55 | 3 |
| Week 7, Any bleeding n=52 | 14 |
| Week 7, Significant bleeding n=52 | 1 |
| Week 8, Any bleeding n=52 | 17 |
| Week 8, Significant bleeding n=52 | 4 |
| Week 9, Any bleeding n=45 | 11 |
| Week 9, Significant bleeding n=45 | 1 |
| Week 10, Any bleeding n=42 | 8 |
| Week 10, Significant bleeding n=42 | 2 |
| Week 11, Any bleeding n=40 | 12 |
| Week 11, Significant bleeding n=40 | 3 |
| Week 12, Any bleeding n=63 | 15 |
| Week 12, Significant bleeding n=63 | 5 |
| Week 13, Any bleeding n=30 | 9 |
| Week 13, Significant bleeding n=30 | 2 |
| Week 14, Any bleeding n=38 | 9 |
| Week 14, Significant bleeding n=38 | 2 |
| Week 15, Any bleeding n=43 | 10 |
| Week 15, Significant bleeding n=43 | 2 |
| Week 16, Any bleeding n=47 | 11 |
| Week 16, Significant bleeding n=47 | 4 |
| Week 17, Any bleeding n=37 | 10 |
| Week 17, Significant bleeding n=37 | 2 |
| Week 18, Any bleeding n=33 | 8 |
| Week 18, Significant bleeding n=33 | 1 |
| Week 19, Any bleeding n=44 | 15 |
| Week 19, Significant bleeding n=44 | 2 |
| Week 20, Any bleeding n=39 | 7 |
| Week 20, Significant bleeding n=39 | 2 |
| Week 21, Any bleeding n=41 | 10 |
| Week 21, Significant bleeding n=41 | 2 |
| Week 22, Any bleeding n=34 | 7 |
| Week 22, Significant bleeding n=34 | 3 |
| Week 23, Any bleeding n=36 | 15 |
| Week 23, Significant bleeding n=36 | 2 |
| Week 24, Any bleeding n=79 | 19 |
| Week 24, Significant bleeding n=79 | 5 |
| Follow-up Week 1, Any bleeding n=29 | 8 |
| Follow-up Week 1, Significant bleeding n=29 | 2 |
| Follow-up Week 2, Any bleeding n=37 | 25 |
| Follow-up Week 2, Significant bleeding n=37 | 5 |
| Follow-up Week 3, Any bleeding n=40 | 17 |
| Follow-up Week 3, Significant bleeding n=40 | 5 |
| Follow-up Week 4, Any bleeding n=70 | 23 |
| Follow-up Week 4, Significant bleeding n=70 | 3 |
| Any follow-up Week, Any bleeding n=77 | 38 |
| Any Follow-up Week, Significant bleeding n=77 | 8 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.
| Participants | Part 1 (Randmoized Period) -Placebo | Part 1 (Randomized Period) - Eltrombopag |
|---|---|---|
| Any AE | 21 | 51 |
| Any SAE | 4 | 5 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening; requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.
| Participants | Part 2 (Open-Label Period) - Eltrombopag |
|---|---|
| Any AE | 69 |
| Any SAE | 9 |
Clinical chemistry parameters were summarized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0: Grade 0 (G0), none; Grade 1 (G1), mild; Grade 2 (G2), moderate; Grade 3 (G3), severe; Grade 4 (G4), life-threatening or disabling. Clinical chemistry parameters included: aspartate amino transferase (AST), alkaline phosphatase (ALP), total bilirubin, albumin, alanine amino transferase (ALT), prothrombin international normalized ratio (PT INR), activated partial thromboplastin time (APTT), and creatinine. The Baseline value is defined as the value taken at Day 1 or, if missing, the latest non-missing Screening value. For serum creatinine, due to the variations in creatinine, the average of the Screening and the Day 1 values will be used as Baseline. The maximum post-Baseline toxicity grade includes any scheduled or unscheduled post-Baseline assessment during Part 1.
| Participants | Part 1 (Randmoized Period)-Placebo | Part 1 (Randomized Period) - Eltrombopag |
|---|---|---|
| AST, G0, n=29, 63 | 26 | 50 |
| AST, G1, n=29, 63 | 3 | 12 |
| AST, G2, n=29, 63 | 0 | 1 |
| AST, G3, n=29, 63 | 0 | 0 |
| AST, G4, n=29, 63 | 0 | 0 |
| ALT, G0, n=29, 63 | 27 | 52 |
| ALT, G1, n=29, 63 | 2 | 6 |
| ALT, G2, n=29, 63 | 0 | 3 |
| ALT, G3, n=29, 63 | 0 | 2 |
| ALT, G4, n=29, 63 | 0 | 0 |
| Total Bilirubin, G0, n=29, 63 | 29 | 60 |
| Total Bilirubin, G1, n=29, 63 | 0 | 3 |
| Total Bilirubin, G2, n=29, 63 | 0 | 0 |
| Total Bilirubin, G3, n=29, 63 | 0 | 0 |
| Total Bilirubin, G4, n=29, 63 | 0 | 0 |
| Albumin, G0, n=29, 63 | 29 | 63 |
| Albumin, G1, n=29, 63 | 0 | 0 |
| Albumin, G2, n=29, 63 | 0 | 0 |
| Albumin, G3, n=29, 63 | 0 | 0 |
| Albumin, G4, n=29, 63 | 0 | 0 |
| ALP, G0, n=29, 63 | 28 | 47 |
| ALP, G1, n=29, 63 | 1 | 16 |
| ALP, G2, n=29, 63 | 0 | 0 |
| ALP, G3, n=29, 63 | 0 | 0 |
| ALP, G4, n=29, 63 | 0 | 0 |
| PT INR, G0, n=27, 58 | 26 | 57 |
| PT INR, G1, n=27, 58 | 1 | 1 |
| PT INR, G2, n=27, 58 | 0 | 0 |
| PT INR, G3, n=27, 58 | 0 | 0 |
| PT INR, G4, n=27, 58 | 0 | 0 |
| APTT, G0 n=27, 58 | 13 | 24 |
| APTT, G1, n=27, 58 | 13 | 32 |
| APTT, G2, n=27, 58 | 1 | 2 |
| APTT, G3, n=27, 58 | 0 | 0 |
| APTT, G4, n=27, 58 | 0 | 0 |
| Creatinine, G0, n=29, 63 | 22 | 47 |
| Creatinine, G1, n=29, 63 | 7 | 15 |
| Creatinine, G2, n=29, 63 | 0 | 1 |
| Creatinine, G3, n=29, 63 | 0 | 0 |
| Creatinine, G4, n=29, 63 | 0 | 0 |
Clinical chemistry parameters were summarized according to the NCI CTCAE, version 4.0: G0, none; G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Clinical chemistry parameters included: AST, ALP, total bilirubin, albumin, ALT, and creatinine. For participants randomized to Placebo in Part 1, the BL value for Part 2 is defined as the value taken at Week 13 of Part 1. For serum creatinine, the value taken at Week 13 of Part 1 will be used as BL. For participants randomized to Eltrombopag in Part 1, the BL value is defined as the value taken on Day 1 or, if missing, the latest non-missing Screening value. For serum creatinine, due to the variations in creatinine, the average of the Screening and the Day 1 values will be used as BL. For participants who do not have both a Screening and Day 1 value, the Screening or Day 1 value will be used as BL. The maximum post-BL toxicity grade includes any scheduled or unscheduled post-BL assessment.
| Participants | Part 2 (Open-Label Period) - Eltrombopag |
|---|---|
| AST, G0 | 63 |
| AST, G1 | 21 |
| AST, G2 | 1 |
| AST, G3 | 2 |
| AST, G4 | 0 |
| ALT, G0 | 67 |
| ALT, G1 | 14 |
| ALT, G2 | 3 |
| ALT, G3 | 3 |
| ALT, G4 | 0 |
| Total Bilirubin, G0 | 80 |
| Total Bilirubin, G1 | 4 |
| Total Bilirubin, G2 | 3 |
| Total Bilirubin, G3 | 0 |
| Total Bilirubin, G4 | 0 |
| Albumin, G0 | 85 |
| Albumin, G1 | 1 |
| Albumin, G2 | 1 |
| Albumin, G3 | 0 |
| Albumin, G4 | 0 |
| ALP, G0 | 67 |
| ALP, G1 | 20 |
| ALP, G2 | 0 |
| ALP, G3 | 0 |
| ALP, G4 | 0 |
| Creatinine, G0 | 72 |
| Creatinine, G1 | 14 |
| Creatinine, G2 | 1 |
| Creatinine, G3 | 0 |
| Creatinine, G4 | 0 |
Hematology parameters were summarized according to the NCI CTCAE, version 4.0: G0, none; G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Hematology parameters included: leukocytes, neutrophils, hemoglobin (increased), hemoglobin (anemia), lymphocytes (increased), and lymphocytes (decreased). The Baseline value is defined as the value taken at Day 1 or, if missing, the latest non-missing Screening value. The maximum post-Baseline toxicity grade includes any scheduled or unscheduled post-Baseline assessment during Part 1.
| Participants | Part 1(Randomized Period)-Placebo | Part 1 (Randomized Period) - Eltrombopag |
|---|---|---|
| Leukocytes, G0, n=29, 63 | 23 | 50 |
| Leukocytes, G1, n=29, 63 | 6 | 11 |
| Leukocytes, G2, n=29, 63 | 0 | 0 |
| Leukocytes, G3, n=29, 63 | 0 | 1 |
| Leukocytes, G4, n=29, 63 | 0 | 1 |
| Neutrophils G0, n=29, 63 | 27 | 52 |
| Neutrophils G1, n=29, 63 | 1 | 3 |
| Neutrophils G2, n=29, 63 | 0 | 6 |
| Neutrophils G3, n=29, 63 | 1 | 0 |
| Neutrophils G4, n=29, 63 | 0 | 2 |
| Hemoglobin (increased), G0, n=29, 63 | 26 | 49 |
| Hemoglobin (increased), G1, n=29, 63 | 3 | 12 |
| Hemoglobin (increased), G2, n=29, 63 | 0 | 2 |
| Hemoglobin (increased), G3, n=29, 63 | 0 | 0 |
| Hemoglobin (increased), G4, n=29, 63 | 0 | 0 |
| Hemoglobin (anemia), G0, n=29, 63 | 20 | 42 |
| Hemoglobin (anemia), G1, n=29, 63 | 7 | 17 |
| Hemoglobin (anemia), G2, n=29, 63 | 0 | 4 |
| Hemoglobin (anemia), G3, n=29, 63 | 2 | 0 |
| Hemoglobin (anemia), G4, n=29, 63 | 0 | 0 |
| Lymphocytes (increased), G0, n=29, 63 | 17 | 37 |
| Lymphocytes (increased), G1, n=29, 63 | 0 | 0 |
| Lymphocytes (increased), G2, n=29, 63 | 12 | 26 |
| Lymphocytes (increased), G3, n=29, 63 | 0 | 0 |
| Lymphocytes (increased), G4, n=29, 63 | 0 | 0 |
| Lymphocytes (decreased), G0, n=29, 63 | 25 | 48 |
| Lymphocytes (decreased), G1, n=29, 63 | 4 | 13 |
| Lymphocytes (decreased), G2, n=29, 63 | 0 | 1 |
| Lymphocytes (decreased), G3, n=29, 63 | 0 | 1 |
| Lymphocytes (decreased), G4, n=29, 63 | 0 | 0 |
Hematology parameters were summarized according to the NCI CTCAE, version 4.0: G0, none, G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Hematology parameters included: leukocytes, neutrophils, hemoglobin (increased), hemoglobin (anemia), lymphocytes (increased), and lymphocytes (decreased). For participants randomized to Placebo in Part 1, the BL value for Part 2 is defined as the value taken at Week 13 of Part 1. For participants randomized to Eltrombopag in Part 1, the BL value is defined as the value taken on Day 1 or, if missing, the latest non-missing Screening value. For participants who do not have both a Screening and Day 1 value, the Screening or Day 1 value will be used as BL. The maximum post-BL toxicity grade includes any scheduled or unscheduled post-BL assessment.
| Participants | Part 2 (Open-Label Period) - Eltrombopag |
|---|---|
| Leukocytes, G0 | 59 |
| Leukocytes, G1 | 23 |
| Leukocytes, G2 | 3 |
| Leukocytes, G3 | 2 |
| Leukocytes, G4 | 0 |
| Neutrophils, G0 | 63 |
| Neutrophils, G1 | 6 |
| Neutrophils, G2 | 13 |
| Neutrophils, G3 | 2 |
| Neutrophils, G4 | 3 |
| Hemoglobin (increased), G0 | 74 |
| Hemoglobin (increased), G1 | 11 |
| Hemoglobin (increased), G2 | 2 |
| Hemoglobin (increased), G3 | 0 |
| Hemoglobin (increased), G4 | 0 |
| Hemoglobin (anemia), G0 | 48 |
| Hemoglobin (anemia), G1 | 31 |
| Hemoglobin (anemia), G2 | 7 |
| Hemoglobin (anemia), G3 | 1 |
| Hemoglobin (anemia), G4 | 0 |
| Lymphocytes (increased), G0 | 47 |
| Lymphocytes (increased), G1 | 0 |
| Lymphocytes (increased), G2 | 40 |
| Lymphocytes (increased), G3 | 0 |
| Lymphocytes (increased), G4 | 0 |
| Lymphocytes (decreased), G0 | 65 |
| Lymphocytes (decreased), G1 | 19 |
| Lymphocytes (decreased), G2 | 2 |
| Lymphocytes (decreased), G3 | 1 |
| Lymphocytes (decreased), G4 | 0 |
Vital sign measurements were taken before any blood draws and included systolic blood pressure(SBP), diastolic blood pressure(DBP), and heart rate(HR). The number of participants are reported with vital sign data falling outside the standard reference ranges RR as reference range high(RRH) and reference range low(RRL). The Baseline(BL) value is defined as the value taken at Day 1 or if missing, the latest non-missing SCR value. RR for Blood Pressure (mmHg) are read as: Lower Limit of Normal, Normal Range, Upper Limit of Normal. For Ages 1 to 5 years (yrs) ranges are SBP \<85, 85 to 115, \>115; DBP \<45, 45 to70, \>70. Ages 6 to 11 yrs: SBP \<85, 85 to 120, \>120;, DBP \<50, 50 to 75, \>75. Ages 12 to 17 yrs: SBP \<95, 95 to 135, \>135; DBP \<55, 55 to 85, \>85. RR for HR(bpm) are ages 1 to \< 3 yrs: \<90, 90 to 140, \>140; ages 3 to \< 5 yrs: \<75, 75 to 130, \>130, ages 5 to \< 8yrs: \<65, 65 to 115, \>115; ages 8 to \< 12yrs: \<55, 55 to 110, \>110; and ages 12 to 18 yrs: \<55, 55 to 110, \>110.
| Participants | Part 1 (Randomized Period)-Placebo | Part 1 (Randomized Period)-Eltrombopag |
|---|---|---|
| DBP, Day 1, RRH, n=28,62 | 6 | 8 |
| DBP, Day 1, RRL, n=28, 62 | 2 | 5 |
| DBP, Week 1, RRH, n=28, 63 | 3 | 10 |
| DBP, Week 1, RRL, n=28, 63 | 0 | 5 |
| DBP, Week 2, RRH, n=29, 63 | 3 | 8 |
| DBP, Week 2, RRL, n=29, 63 | 2 | 6 |
| DBP, Week 3, RRH, n=28, 63 | 7 | 12 |
| DBP, Week 3, RRL, n=28, 63 | 2 | 6 |
| DBP, Week 4, RRH, n=29, 62 | 7 | 5 |
| DBP, Week 4, RRL, n=29, 62 | 2 | 9 |
| DBP, Week 5, RRH, n=27, 62 | 4 | 10 |
| DBP, Week 5, RRL, n=27, 62 | 2 | 6 |
| DBP, Week 6, RRH, n=28, 62 | 7 | 10 |
| DBP, Week 6, RRL, n=28, 62 | 1 | 8 |
| DBP, Week 7, RRH, n=28, 63 | 3 | 7 |
| DBP, Week 7, RRL, n=28, 63 | 2 | 5 |
| DBP, Week 8, RRH, n=28, 63 | 4 | 9 |
| DBP, Week 8, RRL, n=28, 63 | 2 | 8 |
| DBP, Week 9, RRH, n=27, 61 | 4 | 9 |
| DBP, Week 9, RRL, n=27, 61 | 2 | 4 |
| DBP, Week 10, RRH, n=28, 62 | 6 | 8 |
| DBP, Week 10, RRL, n=28, 62 | 2 | 7 |
| DBP, Week 11, RRH, n=28, 61 | 6 | 8 |
| DBP, Week 11, RRL, n=28, 61 | 3 | 6 |
| DBP, Week 12, RRH, n=28, 61 | 3 | 8 |
| DBP, Week 12, RRL, n=28, 61 | 0 | 6 |
| DBP, Week 13, RRH, n=28, 61 | 4 | 9 |
| DBP, Week 13, RRL, n=28, 61 | 3 | 4 |
| Heart Rate, Day 1, RRH, n=28, 62 | 0 | 2 |
| Heart Rate, Day 1, RRL, n=28, 62 | 0 | 1 |
| Heart Rate, Week 1, RRH, n=28, 63 | 0 | 0 |
| Heart Rate, Week 1, RRL, n=28, 63 | 0 | 0 |
| Heart Rate, Week 2, RRH, n=29, 63 | 2 | 1 |
| Heart Rate, Week 2, RRL, n=29, 63 | 0 | 1 |
| Heart Rate, Week 3, RRH, n=28, 63 | 1 | 2 |
| Heart Rate, Week 3, RRL, n=28, 63 | 0 | 0 |
| Heart Rate, Week 4, RRH, n=29, 61 | 0 | 4 |
| Heart Rate, Week 4, RRL, n=29, 61 | 0 | 1 |
| Heart Rate, Week 5, RRH, n=27, 62 | 1 | 5 |
| Heart Rate, Week 5, RRL, n=27, 62 | 1 | 0 |
| Heart Rate, Week 6, RRH, n=28,62 | 1 | 1 |
| Heart Rate, Week 6, RRL, n=28, 62 | 1 | 0 |
| Heart Rate, Week 7, RRH, n=28, 63 | 0 | 2 |
| Heart Rate, Week 7, RRL, n=28, 63 | 1 | 0 |
| Heart Rate, Week 8, RRH, n=28, 63 | 1 | 2 |
| Heart Rate, Week 8, RRL, n=28, 63 | 1 | 0 |
| Heart Rate, Week 9, RRH, n=27, 61 | 1 | 2 |
| Heart Rate, Week 9, RRL, n=27, 61 | 0 | 0 |
| Heart Rate, Week 10, RRH, n=28, 62 | 1 | 1 |
| Heart Rate, Week 10, RRL, n=28, 62 | 0 | 0 |
| Heart Rate, Week 11, RRH, n=28, 61 | 1 | 2 |
| Heart Rate, Week 11, RRL, n=28, 61 | 0 | 0 |
| Heart Rate, Week 12, RRH, n=28,61 | 0 | 2 |
| Heart Rate, Week 12, RRL, n=28, 61 | 0 | 0 |
| Heart Rate, Week 13, RRH, n=28, 61 | 0 | 3 |
| Heart Rate, Week 13, RRL, n=28, 61 | 1 | 0 |
| SBP, Day 1, RRH, n=28, 62 | 5 | 10 |
| SBP, Day 1, RRL, n=28, 62 | 3 | 6 |
| SBP, Week 1, RRH, n=28, 63 | 3 | 11 |
| SBP, Week 1, RRL, n=28,63 | 4 | 8 |
| SBP, Week 2, RRH, n=29, 63 | 4 | 7 |
| SBP, Week 2, RRL, n=29, 63 | 3 | 9 |
| SBP, Week 3, RRH, n=28, 63 | 3 | 9 |
| SBP, Week 3, RRL, n=28, 63 | 2 | 9 |
| SBP, Week 4, RRH, n=29, 62 | 3 | 10 |
| SBP, Week 4, RRL, n=29, 62 | 2 | 9 |
| SBP, Week 5, RRH, n=27, 62 | 5 | 9 |
| SBP, Week 5, RRL, n=27, 62 | 4 | 7 |
| SBP, Week 6, RRH, n=28, 62 | 5 | 7 |
| SBP, Week 6, RRL, n=28, 62 | 3 | 8 |
| SBP, Week 7, RRH, n=28, 63 | 5 | 10 |
| SBP, Week 7, RRL, n=28, 63 | 3 | 7 |
| SBP, Week 8, RRH, n=28, 63 | 3 | 14 |
| SBP, Week 8, RRL, n=28, 63 | 4 | 7 |
| SBP, Week 9, RRH, n=27, 61 | 4 | 12 |
| SBP, Week 9, RRL, n=27, 61 | 3 | 7 |
| SBP, Week 10, RRH, n=28, 62 | 4 | 11 |
| SBP, Week 10, RRL, n=28, 62 | 3 | 11 |
| SBP, Week 11, RRH, n=28, 61 | 6 | 12 |
| SBP, Week 11, RRL, n=28, 61 | 5 | 9 |
| SBP, Week 12, RRH, n=28, 61 | 4 | 11 |
| SBP, Week 12, RRL, n=28, 61 | 4 | 4 |
| SBP, Week 13, RRH, n=28, 61 | 6 | 9 |
| SBP, Week 13, RRL, n=28, 61 | 4 | 7 |
Vital sign measurements were taken before any blood draw and included systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate(HR). The number of participants are reported with vital sign data falling outside the standard RR as reference range high(RRH) and reference range low(RRL) from SCR up to Week 24 of Part 2 and from Follow-up Week 1 to Week 4. RR for Blood Pressure(mmHg) are read as: Lower Limit of Normal, Normal Range, Upper Limit of Normal. For Ages 1 to 5 years (yrs) ranges are SBP \<85, 85 to 115, \>115; DBP \<45, 45 to70, \>70. Ages 6 to 11 yrs: SBP \<85, 85 to 120, \>120; DBP \<50, 50 to 75, \>75. Ages 12 to 17 yrs: SBP \<95, 95 to 135, \>135; DBP \<55, 55 to 85, \>85. RR for HR (bpm) are ages 1 to \< 3 yrs: \<90, 90 to 140, \>140; ages 3 to \< 5 yrs: \<75, 75 to 130, \>130, ages 5 to \< 8yrs: \<65, 65 to 115, \>115; ages 8 to \< 12yrs: \<55, 55 to 110, \>110; and ages 12 to 18 yrs: \<55, 55 to 110, \>110.
| Participants | Part 2 (Open-Label Period) - Eltrombopag |
|---|---|
| DBP, Week 1, RRH, n=87 | 14 |
| DBP, Week 1, RRL, n=87 | 8 |
| DBP, Week 2, RRH, n=86 | 14 |
| DBP, Week 2, RRL, n=86 | 8 |
| DBP, Week 3, RRH, n=86 | 13 |
| DBP, Week 3, RRL, n=86 | 11 |
| DBP, Week 4, RRH, n=68 | 10 |
| DBP, Week 4, RRL, n=68 | 7 |
| DBP, Week 5, RRH, n=61 | 7 |
| DBP, Week 5, RRL, n=61 | 7 |
| DBP, Week 6, RRH, n=55 | 6 |
| DBP, Week 6, RRL, n=55 | 4 |
| DBP, Week 7, RRH, n=52 | 7 |
| DBP, Week 7, RRL, n=52 | 5 |
| DBP, Week 8, RRH, n=53 | 4 |
| DBP, Week 8, RRL, n=53 | 6 |
| DBP, Week 9, RRH, n=45 | 3 |
| DBP, Week 9, RRL, n=45 | 7 |
| DBP, Week 10, RRH, n=42 | 5 |
| DBP, Week 10, RRL, n=42 | 7 |
| DBP, Week 11, RRH, n=40 | 5 |
| DBP, Week 11, RRL, n=40 | 7 |
| DBP, Week 12, RRH, n=63 | 9 |
| DBP, Week 12, RRL, n=63 | 11 |
| DBP, Week 13, RRH, n=29 | 4 |
| DBP, Week 13, RRL, n=29 | 2 |
| DBP, Week 14, RRH, n=38 | 2 |
| DBP, Week 14, RRL, n=38 | 9 |
| DBP, Week 15, RRH, n=43 | 7 |
| DBP, Week 15, RRL, n=43 | 3 |
| DBP, Week 16, RRH, n=47 | 3 |
| DBP, Week 16, RRL, n=47 | 6 |
| DBP, Week 17, RRH, n=37 | 5 |
| DBP, Week 17, RRL, n=37 | 6 |
| DBP, Week 18, RRH, n=34 | 7 |
| DBP, Week 18, RRL, n=34 | 5 |
| DBP, Week 19, RRH, n=44 | 5 |
| DBP, Week 19, RRL, n=44 | 3 |
| DBP, Week 20, RRH, n=39 | 6 |
| DBP, Week 20, RRL, n=39 | 3 |
| DBP, Week 21, RRH, n=41 | 9 |
| DBP, Week 21, RRL, n=41 | 6 |
| DBP, Week 22, RRH, n=34 | 6 |
| DBP, Week 22, RRL, n=34 | 3 |
| DBP, Week 23, RRH, n=36 | 6 |
| DBP, Week 23, RRL, n=36 | 6 |
| DBP, Week 24, RRH, n=79 | 14 |
| DBP, Week 24, RRL, n=79 | 10 |
| DBP, Follow-Up Week 1, RRH, n=29 | 8 |
| DBP, Follow-Up Week 1, RRL, n=29 | 3 |
| DBP, Follow-Up Week 2, RRH, n=37 | 8 |
| DBP, Follow-Up Week 2, RRL, n=37 | 6 |
| DBP, Follow-Up Week 3, RRH, n=39 | 4 |
| DBP, Follow-Up Week 3, RRL, n=39 | 5 |
| DBP, Follow-Up Week 4, RRH, n=67 | 8 |
| DBP, Follow-Up Week 4, RRL, n=67 | 5 |
| Heart Rate, Week 1, RRH, n=87 | 4 |
| Heart Rate, Week 1, RRL, n=87 | 1 |
| Heart Rate, Week 2, RRH, n=86 | 3 |
| Heart Rate, Week 2, RRL, n=86 | 2 |
| Heart Rate, Week 3, RRH, n=86 | 1 |
| Heart Rate, Week 3, RRL, n=86 | 0 |
| Heart Rate, Week 4, RRH, n=68 | 2 |
| Heart Rate, Week 4, RRL, n=68 | 0 |
| Heart Rate, Week 5, RRH, n=61 | 0 |
| Heart Rate, Week 5, RRL, n=61 | 1 |
| Heart Rate, Week 6, RRH, n=55 | 1 |
| Heart Rate, Week 6, RRL, n=55 | 0 |
| Heart Rate, Week 7, RRH, n=52 | 2 |
| Heart Rate, Week 7, RRL, n=52 | 0 |
| Heart Rate, Week 8, RRH, n=53 | 2 |
| Heart Rate, Week 8, RRL, n=53 | 0 |
| Heart Rate, Week 9, RRH, n=45 | 2 |
| Heart Rate, Week 9, RRL, n=45 | 0 |
| Heart Rate, Week 10, RRH, n=42 | 1 |
| Heart Rate, Week 10, RRL, n=42 | 1 |
| Heart Rate, Week 11, RRH, n=40 | 1 |
| Heart Rate, Week 11, RRL, n=40 | 1 |
| Heart Rate, Week 12, RRH, n=63 | 1 |
| Heart Rate, Week 12, RRL, n=63 | 1 |
| Heart Rate, Week 13, RRH, n=29 | 2 |
| Heart Rate, Week 13, RRL, n=29 | 0 |
| Heart Rate, Week 14, RRH, n=38 | 2 |
| Heart Rate, Week 14, RRL, n=38 | 1 |
| Heart Rate, Week 15, RRH, n=43 | 0 |
| Heart Rate, Week 15, RRL, n=43 | 0 |
| Heart Rate, Week 16, RRH, n=47 | 2 |
| Heart Rate, Week 16, RRL, n=47 | 0 |
| Heart Rate, Week 17, RRH, n=37 | 2 |
| Heart Rate, Week 17, RRL, n=37 | 1 |
| Heart Rate, Week 18, RRH, n=34 | 0 |
| Heart Rate, Week 18, RRL, n=34 | 0 |
| Heart Rate, Week 19, RRH, n=44 | 0 |
| Heart Rate, Week 19, RRL, n=44 | 1 |
| Heart Rate, Week 20, RRH, n=39 | 2 |
| Heart Rate, Week 20, RRL, n=39 | 0 |
| Heart Rate, Week 21, RRH, n=41 | 0 |
| Heart Rate, Week 21, RRL, n=41 | 0 |
| Heart Rate, Week 22, RRH, n=34 | 2 |
| Heart Rate, Week 22, RRL, n=34 | 0 |
| Heart Rate, Week 23, RRH, n=36 | 0 |
| Heart Rate, Week 23, RRL, n=36 | 0 |
| Heart Rate, Week 24, RRH, n=79 | 1 |
| Heart Rate, Week 24, RRL, n=79 | 1 |
| Heart Rate, Follow-Up Week 1, RRH, n=29 | 1 |
| Heart Rate, Follow-Up Week 1, RRL, n=29 | 0 |
| Heart Rate, Follow-Up Week 2, RRH, n=37 | 2 |
| Heart Rate, Follow-Up Week 2, RRL, n=37 | 1 |
| Heart Rate, Follow-Up Week 3, RRH, n=39 | 2 |
| Heart Rate, Follow-Up Week 3, RRL, n=39 | 0 |
| Heart Rate, Follow-Up Week 4, RRH, n=67 | 2 |
| Heart Rate, Follow-Up Week 4, RRL, n=67 | 2 |
| SBP, Week 1, RRH, n=87 | 13 |
| SBP, Week 1, RRL, n=87 | 9 |
| SBP, Week 2, RRH, n=86 | 19 |
| SBP, Week 2, RRL, n=86 | 16 |
| SBP, Week 3, RRH, n=86 | 15 |
| SBP, Week 3, RRL, n=86 | 13 |
| SBP, Week 4, RRH, n=68 | 10 |
| SBP, Week 4, RRL, n=68 | 7 |
| SBP, Week 5, RRH, n=61 | 7 |
| SBP, Week 5, RRL, n=61 | 8 |
| SBP, Week 6, RRH, n=55 | 11 |
| SBP, Week 6, RRL, n=55 | 7 |
| SBP, Week 7, RRH, n=52 | 10 |
| SBP, Week 7, RRL, n=52 | 5 |
| SBP, Week 8, RRH, n=53 | 8 |
| SBP, Week 8, RRL, n=53 | 5 |
| SBP, Week 9, RRH, n=45 | 8 |
| SBP, Week 9, RRL, n=45 | 9 |
| SBP, Week 10, RRH, n=42 | 4 |
| SBP, Week 10, RRL, n=42 | 4 |
| SBP, Week 11, RRH, n=40 | 4 |
| SBP, Week 11, RRL, n=40 | 6 |
| SBP, Week 12, RRH, n=63 | 14 |
| SBP, Week 12, RRL, n=63 | 10 |
| SBP, Week 13, RRH, n=29 | 3 |
| SBP, Week 13, RRL, n=29 | 2 |
| SBP, Week 14, RRH, n=38 | 5 |
| SBP, Week 14, RRL, n=38 | 7 |
| SBP, Week 15, RRH, n=43 | 9 |
| SBP, Week 15, RRL, n=43 | 7 |
| SBP, Week 16, RRH, n=47 | 7 |
| SBP, Week 16, RRL, n=47 | 6 |
| SBP, Week 17, RRH, n=37 | 9 |
| SBP, Week 17, RRL, n=37 | 4 |
| SBP, Week 18, RRH, n=34 | 6 |
| SBP, Week 18, RRL, n=34 | 5 |
| SBP, Week 19, RRH, n=44 | 7 |
| SBP, Week 19, RRL, n=44 | 4 |
| SBP, Week 20, RRH, n=39 | 5 |
| SBP, Week 20, RRL, n=39 | 5 |
| SBP, Week 21, RRH, n=41 | 10 |
| SBP, Week 21, RRL, n=41 | 6 |
| SBP, Week 22, RRH, n=34 | 6 |
| SBP, Week 22, RRL, n=34 | 4 |
| SBP, Week 23, RRH, n=36 | 6 |
| SBP, Week 23, RRL, n=36 | 3 |
| SBP, Week 24, RRH, n=79 | 13 |
| SBP, Week 24, RRL, n=79 | 12 |
| SBP, Follow-Up Week 1, RRH, n=29 | 5 |
| SBP, Follow-Up Week 1, RRL, n=29 | 3 |
| SBP, Follow-Up Week 2, RRH, n=37 | 5 |
| SBP, Follow-Up Week 2, RRL, n=37 | 7 |
| SBP, Follow-Up Week 3, RRH, n=39 | 9 |
| SBP, Follow-Up Week 3, RRL, n=39 | 4 |
| SBP, Follow-Up Week 4, RRH, n=67 | 9 |
| SBP, Follow-Up Week 4, RRL, n=67 | 7 |
The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. Change in visual acuity results are presented as No (no change from Baseline), Not Clinically Significant (NCS), Improvement, and Worsening since Baseline. The Baseline value was obtained at the Screening Visit.
| Participants | EPart 1 (Randomized Period)-Placebo | Part 1 (Randomized Period)-Eltrombopag |
|---|---|---|
| No Change | 22 | 47 |
| NCS | 4 | 8 |
| Improvement | 1 | 2 |
| Worsening | 0 | 1 |
| Not Measured | 2 | 5 |
The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. Change in visual acuity results are presented as No Change, NCS, Improvement, and Worsening since Baseline. The Baseline value was obtained at the Screening Visit.
| Participants | Part 2 (Open-Label Period) - Eltrombopag |
|---|---|
| No Change | 58 |
| NCS | 13 |
| Improvement | 3 |
| Worsening | 6 |
| Not Measured | 7 |
The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. Change in visual acuity results are presented as No Change, NCS, Improvement, and Worsening since Baseline. The Baseline value was obtained at the Screening Visit.
| Participants | Part 2 (Open-Label Period) - Eltrombopag |
|---|---|
| No Change | 63 |
| NCS | 12 |
| Improvement | 9 |
| Worsening | 2 |
| Not Measured | 1 |
The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. The number of participants with worsening visual acuity due to cataracts at Week 12 of Part 1 are presented. Change due to cataracts is categorized as "Yes" or "No."
| Participants | Part 1 (Randomized Period) - Placebo | Part 1 (Randomized Period) - Eltrombopag |
|---|---|---|
| Yes | — | 0 |
| No | — | 1 |
The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. The number of participants with worsening visual acuity due to cataracts at Week 24 of Part 2 are presented. Change due to cataracts is categorized as "Yes" or "No.
| Participants | Part 2 (Open-Label Period) - Eltrombopag |
|---|---|
| Yes | 1 |
| No | 5 |
The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. The number of participants with worsening visual acuity due to cataracts at Follow-up Week 24 are presented. Change due to cataracts is categorized as "Yes" or "No."
| Participants | Part 2 (Open-Label Period) - Eltrombopag |
|---|---|
| Yes | 0 |
| No | 2 |
Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. AUC(0-t) is defined as the area under the concentration-time curve over the dosing interval. The AUC(0-t) for a 50mg dose was estimated for each cohort. From the final model, a single value of each PK parameter was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.
| micrograms*hour per milliliter (ug.h/mL) | Eltrombopag Cohort 1 (12-17 Years) | Eltrombopag Cohort 2 (6-11 Years) | Eltrombopag Cohort 3 (1-5 Years) |
|---|---|---|---|
| Pharmacokinetic (PK) Assessments for Eltrombopag for AUC (0-t) | 104 (86.1 to 126) | 171 (147 to 200) | 184 (147 to 230) |
Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. Cmax is defined as the maximum observed concentration. The Cmax for a 50mg dose was estimated for each cohort. From the final model, a single value of each PK parameter was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.
| micrograms per milliliter (ug/mL) | Eltrombopag Cohort 1 (12-17 Years) | Eltrombopag Cohort 2 (6-11 Years) | Eltrombopag Cohort 3 (1-5 Years) |
|---|---|---|---|
| Pharmacokinetic (PK) Assessments for Eltrombopag for Cmax | 6.94 (5.96 to 8.08) | 11.2 (9.91 to 12.8) | 12.5 (10.7 to 14.6) |
Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. CL/F is defined as the apparent oral clearance from plasma and Q/F is defined as apparent intercompartmental clearance. These parameters are dose independent. From the final model, a single value of each PK parameter was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort.
| Liters per hour (L/hr) | Eltrombopag Cohort 1 (12-17 Years) | Eltrombopag Cohort 2 (6-11 Years) | Eltrombopag Cohort 3 (1-5 Years) |
|---|---|---|---|
| CL/F | 0.48 (0.40 to 0.58) | 0.29 (0.25 to 0.34) | 0.19 (0.15 to 0.24) |
| Q/F | 0.61 (0.54 to 0.68) | 0.38 (0.34 to 0.42) | 0.24 (0.20 to 0.28) |
Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. Vc/F is defined as the volume of the central (e.g. plasma) compartment and Vp/F is defined as the volume of the peripheral compartment. These parameters are dose independent. From the final model, a single value of each PK parameter was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort.
| Liters (L) | Eltrombopag Cohort 1 (12-17 Years) | Eltrombopag Cohort 2 (6-11 Years) | Eltrombopag Cohort 3 (1-5 Years) |
|---|---|---|---|
| Vc/F | 2.46 (2.20 to 2.75) | 1.57 (1.35 to 1.81) | 0.90 (0.76 to 1.05) |
| Vp/F | 19.2 (17.7 to 20.9) | 11.8 (10.9 to 12.9) | 7.17 (6.58 to 7.81) |
Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. Ka is defined as the absorption rate constant. This parameter is dose independent, and the population estimate Ka is reported.
| 1/h | Eltrombopag Cohort 1 (12-17 Years) | Eltrombopag Cohort 2 (6-11 Years) | Eltrombopag Cohort 3 (1-5 Years) |
|---|---|---|---|
| Population PK Model Point Estimate for Eltrombopag for Absorption Rate-constant (Ka) | 0.189 | 0.189 | 0.189 |
Collected over On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of investigational product until follow up (up to 61 weeks).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Eltrombopag | — | 5/63 (7.9%) | 51/63 (81%) |
| Part 1: Placebo | — | 4/29 (13.8%) | 19/29 (65.5%) |
| Part 2: Eltrombopag | — | 9/87 (10.3%) | 68/87 (78.2%) |
| Event | Part 1: Eltrombopag | Part 1: Placebo | Part 2: Eltrombopag |
|---|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/63 | 1/29 | 2/87 |
| PetechiaeSkin and subcutaneous tissue disorders | 0/63 | 1/29 | 0/87 |
| HaemorrhageVascular disorders | 0/63 | 1/29 | 0/87 |
| Hypertensive crisisVascular disorders | 0/63 | 1/29 | 0/87 |
| GingivitisInfections and infestations | 1/63 | 0/29 | 0/87 |
| InfluenzaInfections and infestations | 1/63 | 0/29 | 0/87 |
| Meningitis asepticInfections and infestations | 1/63 | 0/29 | 0/87 |
| PneumoniaInfections and infestations | 1/63 | 0/29 | 1/87 |
| Pneumonia fungalInfections and infestations | 1/63 | 0/29 | 0/87 |
| Alanine aminotransferase abnormalInvestigations | 1/63 | 0/29 | 0/87 |
| Event | Part 1: Eltrombopag | Part 1: Placebo | Part 2: Eltrombopag |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 11/63 | 2/29 | 7/87 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 8/63 | 5/29 | 11/87 |
| RhinitisInfections and infestations | 10/63 | 2/29 | 3/87 |
| Abdominal pain upperGastrointestinal disorders | 3/63 | 4/29 | 3/87 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/63 | 0/29 | 8/87 |
| Upper respiratory tract infectionInfections and infestations | 7/63 | 1/29 | 9/87 |
| HeadacheNervous system disorders | 6/63 | 3/29 | 8/87 |
| PyrexiaGeneral disorders | 4/63 | 1/29 | 9/87 |
| VomitingGastrointestinal disorders | 2/63 | 3/29 | 6/87 |
| Abdominal painGastrointestinal disorders | 6/63 | 0/29 | 7/87 |
| Age, Continuous(Years) | Placebo | Eltrombopag | Total |
|---|---|---|---|
| Mean | 9.8 ± 4.00 | 9.4 ± 4.43 | 9.6 ± 4.22 |
| Sex: Female, Male(Participants) | Placebo | Eltrombopag | Total |
|---|---|---|---|
| Female | 14 | 30 | 44 |
| Male | 15 | 33 | 48 |
| Race/Ethnicity, Customized(Participants) | Placebo | Eltrombopag | Total |
|---|---|---|---|
| African American/African Heritage | 0 | 1 | 1 |
| Central/South Asian Heritage | 0 | 1 | 1 |
| Japanese/East Asian/South East Asian Heritage | 10 | 20 | 30 |
| Arabic/North African Heritage | 1 | 2 | 3 |
| White/Caucasian/European Heritage | 18 | 38 | 56 |
| Mixed Race | 0 | 1 | 1 |
The record gives a start of Mar 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag
Purpura, Thrombocytopenic, Idiopathic →